At ARVO 2025, in Salt Lake City, Utah, Peng Shang, PhD, talked about her presentation on how the Y402H polymorphism of ...

Belite Bio recently announced the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the ...

LUMIFY eye drops were initially introduced by Bausch + Lomb in 2018 and remain the only OTC redness relievers that ...

At ARVO 2025, in Salt Lake City, Utah, David Almeida, MD, MBA, PhD, talked about 12-month results from the PAVIA phase 2 ...

Kapil Mishra, MD, discusses his presentation title "Radiation Retinopathy: Future Strategies" given at the 2025 Retina World ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Viridian Therapeutics reveals promising long-term results for veligrotug in treating thyroid eye disease, highlighting its ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

A recent study reveals a significant rise in childhood astigmatism linked to the COVID-19 pandemic, independent of myopia.

Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer’s Disease and ...

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.